Semagacestat

Semagacestat
Clinical data
Other namesLY-450139
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
  • Development terminated
Pharmacokinetic data
MetabolismCYP3A4, 3A5[1]
Elimination half-life2.4 hours in circulation
Excretion87% renal (44% unchanged, 43% as metabolites)
Identifiers
  • (2S)-2-Hydroxy-3-methyl-N-((1S)-1-methyl-2-{[(1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]amino}-2-oxoethyl)butanamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.318.475 Edit this at Wikidata
Chemical and physical data
FormulaC19H27N3O4
Molar mass361.442 g·mol−1
3D model (JSmol)
  • C[C@@H](C(=O)N[C@H]1C2=CC=CC=C2CCN(C1=O)C)NC(=O)[C@H](C(C)C)O
  • InChI=1S/C19H27N3O4/c1-11(2)16(23)18(25)20-12(3)17(24)21-15-14-8-6-5-7-13(14)9-10-22(4)19(15)26/h5-8,11-12,15-16,23H,9-10H2,1-4H3,(H,20,25)(H,21,24)/t12-,15-,16-/m0/s1 ☒N
  • Key:PKXWXXPNHIWQHW-RCBQFDQVSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Semagacestat (LY-450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Elan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients,[2][3] but in August 2010, a disappointing interim analysis, in which semagacestat performed worse than the placebo, led to the trials being stopped.

  1. ^ Cite error: The named reference pmid20075192 was invoked but never defined (see the help page).
  2. ^ Cite error: The named reference Spreitzer was invoked but never defined (see the help page).
  3. ^ Cite error: The named reference Prous was invoked but never defined (see the help page).